North China Pharmaceutical (600812) Fundamentals 2026 — P/E 51.0x, Revenue Analysis | SniperIQ
North China Pharmaceutical (600812) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥8.3B, trading at ¥4.81 on the SHH. This SniperIQ fundamentals page covers North China Pharmaceutical's valuation (P/E 51.0x, P/B 1.5x), profitability (net margin 1.8%), revenue (¥9.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is North China Pharmaceutical's market cap?
North China Pharmaceutical (600812) has a market capitalization of approximately ¥8.3B, trading at ¥4.81 on the SHH. Market cap moves with the live share price.
What is North China Pharmaceutical's P/E ratio?
North China Pharmaceutical's trailing twelve-month P/E ratio is 51.0x, with a price-to-book (P/B) of 1.5x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is North China Pharmaceutical?
North China Pharmaceutical runs a net profit margin of 1.8%, a gross margin of 31.0%, and an operating margin of 4.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does North China Pharmaceutical generate?
North China Pharmaceutical reported revenue of ¥9.2B for fiscal year 2025, with net income of ¥183M and earnings per share (EPS) of 0.11. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does North China Pharmaceutical pay a dividend?
North China Pharmaceutical offers a trailing dividend yield of about 0.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is North China Pharmaceutical financially healthy?
North China Pharmaceutical carries a debt-to-equity ratio of 2.11x and a current ratio of 0.72x, with a market beta of 0.25. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is North China Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For North China Pharmaceutical (600812) the key facts are: market cap ¥8.3B, P/E 51.0x, revenue ¥9.2B, 52-week range 4.11-7.46. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track North China Pharmaceutical's full fundamentals live
Get North China Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.